Scholar Rock Holding Management

Management criteria checks 3/4

Scholar Rock Holding's CEO is Jay Backstrom, appointed in Oct 2022, has a tenure of 1.58 years. total yearly compensation is $4.11M, comprised of 15.2% salary and 84.8% bonuses, including company stock and options. directly owns 0.032% of the company’s shares, worth €254.60K. The average tenure of the management team and the board of directors is 2.2 years and 7.6 years respectively.

Key information

Jay Backstrom

Chief executive officer

US$4.1m

Total compensation

CEO salary percentage	15.2%
CEO tenure	1.6yrs
CEO ownership	0.03%
Management average tenure	2.2yrs
Board average tenure	7.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jay Backstrom's remuneration changed compared to Scholar Rock Holding's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$183m
Dec 31 2023	US$4m	US$624k	-US$166m
Sep 30 2023	n/a	n/a	-US$159m
Jun 30 2023	n/a	n/a	-US$160m
Mar 31 2023	n/a	n/a	-US$166m
Dec 31 2022	US$7m	US$159k	-US$135m

Compensation vs Market: Jay's total compensation ($USD4.11M) is above average for companies of similar size in the German market ($USD1.28M).

Compensation vs Earnings: Jay's compensation has been consistent with company performance over the past year.

CEO

Jay Backstrom (68 yo)

1.6yrs

Tenure

US$4,111,853

Compensation

Dr. Jay Thomas Backstrom, M.D., M.P.H., serves as Non-Executive Director of LAVA Therapeutics N.V. since June 2022. He serves as Director at Be Biopharma, Inc. since December 2021. He had served as a Direc...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jay Backstrom	President	1.6yrs	US$4.11m	0.032% $ 254.6k
Edward Myles	CFO, COO & Treasurer	3.8yrs	US$2.01m	0.031% $ 245.6k
Tracey Sacco	Chief Commercial Officer	1.3yrs	US$2.28m	0% $ 0
Mo Qatanani	Chief Scientific Officer	less than a year	no data	0.013% $ 102.7k
Rushmie Nofsinger	Vice President of Corporate Affairs & Investor Relations	no data	no data	no data
Junlin Ho	General Counsel & Corporate Secretary	4.2yrs	US$2.13m	0.080% $ 627.3k
Caryn Parlavecchio	Chief Human Resources Officer	2.8yrs	no data	0.037% $ 289.7k
Lisa Price	Senior Vice President of Human Resources	no data	no data	no data
Erin Moore	Senior Vice President of Finance	no data	no data	no data
Ryan Iarrobino	Senior Vice President of Clinical Development & Operations	4.2yrs	no data	no data
Jing Marantz	Chief Medical Officer	1.5yrs	no data	no data

2.2yrs

Average Tenure

50.5yo

Average Age

Experienced Management: 2QK's management team is considered experienced (2.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jay Backstrom	President	1.6yrs	US$4.11m	0.032% $ 254.6k
Michael Gilman	Independent Director & Member of Scientific Advisory Board	10.5yrs	US$299.20k	0.047% $ 368.4k
Timothy Springer	Member of Scientific Advisory Board	no data	US$48.97k	no data
Amir Nashat	Independent Director	11.6yrs	US$295.70k	0.050% $ 394.4k
Jeffrey Flier	Independent Director & Member of Scientific Advisory Board	7.6yrs	US$305.70k	0.011% $ 88.6k
Leonard Zon	Member of Scientific Advisory Board	no data	no data	no data
Kristina Burow	Independent Director	9.8yrs	US$300.34k	0.0067% $ 52.5k
Joan Massague	Member of Scientific Advisory Board	no data	no data	no data
David Hallal	Independent Chairman of the Board	6.8yrs	US$416.70k	0.36% $ 2.9m
Scott L. Friedman	Member of Scientific Advisory Board	no data	no data	no data
Barry Coller	Member of Scientific Advisory Board	no data	no data	no data
Joshua Reed	Independent Director	3.2yrs	US$305.70k	0% $ 0

7.6yrs

Average Tenure

68yo

Average Age

Experienced Board: 2QK's board of directors are considered experienced (7.6 years average tenure).

Scholar Rock Holding Management

Management criteria checks 3/4

Key information

Recent management updates

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

President recently sold €170k worth of stock

Scholar Rock Announces Management Appointments

Senior VP & Head of Research recently sold €268k worth of stock

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Recent updates

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

New major risk - Financial position

President recently sold €170k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Senior VP & Head of Research recently sold €268k worth of stock

New major risk - Revenue and earnings growth

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Full year 2022 earnings released: US$2.26 loss per share (vs US$3.59 loss in FY 2021)

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer

Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock Announces Chief Executive Officer Changes

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index

Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment

Scholar Rock Holding Corporation Provides Pipeline Updates

First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.76 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022

Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020)

Scholar Rock Holding Corporation Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.65 loss in 2Q 2020)

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress

Forecast to breakeven in 2025

Scholar Rock Announces Oral Presentation of TOPAZ Phase 2 Trail Results at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy

Scholar Rock Holding Corporation to Present Trials in Progress Poster for Srk-181 Dragon Phase 1 Clinical Trial At the American Society of Clinical Oncology Annual Meeting

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.76 loss per share (vs US$0.58 loss in 1Q 2020)

Scholar Rock Announces Publication of Phase 1 Clinical Trial Data Evaluating Apitegromab in Healthy Volunteers in the Journal Advances in Therapy

Scholar Rock Announces the Addition of Joshua Reed to Its Board of Directors

Full year 2020 earnings released: US$2.81 loss per share (vs US$1.85 loss in FY 2019)

Revenue misses expectations

New 90-day high: €50.00

Scholar Rock Announces Executive Promotions

New 90-day high: €47.40

New 90-day high: €43.80

Third quarter 2020 earnings released: US$0.79 loss per share

Revenue misses expectations

New 90-day high: €31.80

Earnings released

Scholar Rock Holding Corporation to Report Q2, 2020 Results on Aug 07, 2020

Scholar Rock Holding Corporation Announces Executive Changes, Effective August 1, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age